Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.

• Presentation: Ocular Therapeutix: Retina Experience RedefinedPresentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDTPresenter: Peter K. Kaiser, MD, Chief Development Officer

• Panel Title: The Impact of Recent FDA Guidance on Drug DevelopmentPanel Date/Time: Tuesday, July 14, 2026, 4:40 – 5:20 PM ETPanel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO

• Presentation: Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3SOL-1 Trial ResultsSession: Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMDPresentation Date/Time: Thursday, July 16, 2026, 8:15 – 8:45 AM EDTPresenter: Dilsher S. Dhoot, MD

• Presentation: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum DatabaseSession: Real-world nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF DataPresentation Date/Time: Thursday, July 16, 2026, 8:50 – 8:53 AM EDTPresenter: Andrew A. Moshfeghi, MD, MBA, FASRS

• On-Demand Paper Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS RegistrySession Date/Time: On-demand papers will be continually available for viewing throughout the meetingPresenter: Priya Vakharia, MD

• Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease ControlSession: Satellite SymposiaSymposium Date/Time: Thursday, July 16, 2026, 6:00 – 7:30 PM EDTFaculty: Arshad M. Khanani, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD; Peter K. Kaiser, MD, Chief Development Officer; and Jeffrey S. Heier, MD, Chief Scientific Officer

Exact medical conference presentation times may be subject to change.

HC Wainwright 6thAnnual Ophthalmology Virtual Conference:Date: Wednesday, July 22, 2026Fireside Chat: 4:30 – 5:00 PM EDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Virtual

A live webcast of the fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.

About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA®is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.